PEPTIDE RESEARCH TOPIC

Tesamorelin Research Peptide

Browse Tesamorelin information, terminology, research context, comparisons, storage, and analytical documentation.

TOPIC OVERVIEW

About Tesamorelin

Identity and names

Tesamorelin is the formal active-compound name; Tesa and Tesa peptide are informal abbreviations.

  • EGRIFTA product names identify specific regulated formulations and should not be used as synonyms for every material described as tesamorelin.

Compound type

Tesamorelin is a modified analogue of human growth hormone-releasing hormone.

  • It is mechanistically different from growth hormone itself and from ghrelin-receptor secretagogues such as Ipamorelin.

Mechanism

Tesamorelin activates GHRH receptors on pituitary somatotroph cells.

  • This stimulates endogenous pulsatile growth-hormone release, followed by changes in IGF-1 and related binding proteins rather than direct administration of growth hormone.

Research focus and evidence

The evidence base includes receptor research and controlled human trials for a defined regulated use and population.

  • This category covers endocrine markers, formulation, storage, analytical identity, and comparisons with Sermorelin, CJC-1295, and secretagogues.

Regulatory status and limits

FDA authorization applies to named tesamorelin products for a specific indication; the current label states that the product is not indicated for weight-loss management.

  • That evidence does not automatically apply to other indications, compounded preparations, or research-labeled material, and tesamorelin is also prohibited in sport under current World Anti-Doping Agency rules.
Topics covered
  • GHRH signaling terminology
  • endocrine research context
  • comparison with secretagogues
  • storage and handling
  • purity and identity documentation
Common names and related terms: tesamorelin, tesa, tesa peptide
RESEARCH TRACKER

Tesamorelin Development & Clinical Research

Current programs, research areas, study status, enrollment, and expected completion dates organized from primary registry records.

LAST VERIFIEDSeptember 30, 2026
Registered records24
Active studies3
Completed studies14
FDA-listed brands1
DeveloperTheratechnologies
AliasesTH9507, Egrifta
Biological targetsGrowth hormone-releasing hormone receptor
Development stageApproved medicine with ongoing clinical research
Regulatory statusFDA-approved formulation exists

What current projects are studying

Metabolic Associated Steatotic Liver DiseaseNonalcoholic SteatohepatitisHepatic SteatosisHIV-1-infectionFrailtyImpaired Physical FunctionAbdominal ObesityAging
SELECTED CURRENT RESEARCH

Latest and important projects

Showing 3 of 3 active studies
TESA-LIVERNCT07481734

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

Metabolic Associated Steatotic Liver Disease · Nonalcoholic Steatohepatitis · Hepatic Steatosis

Phase
Phase 2
Status
Recruiting
Enrollment
120 Estimated
Expected completion
Feb 17, 2028
Record updated
Mar 19, 2026
Lead sponsor
Hudson Biotech
TRIUMPHNCT06554717

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

HIV-1-infection · Frailty · Impaired Physical Function · Abdominal Obesity · Aging

Phase
Phase 2
Status
Recruiting
Enrollment
100 Estimated
Expected completion
Dec 1, 2028
Record updated
May 19, 2026
Lead sponsor
Massachusetts General Hospital
REGISTERED STUDYNCT03150511

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Peripheral Nerve Injuries

Phase
Phase 2
Status
Recruiting
Enrollment
36 Estimated
Expected completion
Dec 2027
Record updated
Nov 12, 2025
Lead sponsor
Johns Hopkins University
Primary sources: ClinicalTrials.gov · FDA Drugs@FDA — Egrifta (tesamorelin), NDA 022505Counts reflect a dated ClinicalTrials.gov intervention search. Selected current projects are shown for orientation; records require entity review before longitudinal comparisons.

Registry status does not establish safety, efficacy, or regulatory approval.

START HERE

Essential Tesamorelin guides

TESAMORELIN KNOWLEDGE ARTICLESPage 1 of 13
04
KNOWLEDGE ARTICLE

Tesamorelin Capsules: Do They Exist? What to Know

Tesamorelin capsules are not an approved form of the drug — the FDA-approved version is a daily injection. What kits, pens, and research vials really are.

↗
12
KNOWLEDGE ARTICLE

CJC-1295 No DAC vs With DAC: Key Differences

CJC-1295 no DAC vs with DAC explained: half-life, dosing, research use, and side effects, plus how each compares to ipamorelin and tesamorelin.

↗
15
KNOWLEDGE ARTICLE

CJC-1295 Cycle: Length, Protocol & Safety

Understand the CJC-1295 cycle, including typical length, dosing schedules, safety, and how it compares to peptides like ipamorelin and tesamorelin.

↗